Business Context and Reporting Period
This Form 8-K Current Report was filed by 4D Molecular Therapeutics, Inc. on October 2, 2025, covering events that occurred on September 30, 2025. The company is a clinical-stage biopharmaceutical entity incorporated in Delaware, with its principal executive offices in Emeryville, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and personnel changes rather than financial performance data.
Material Changes
- Executive Appointment: The Board appointed Ashoo Gupta as Principal Financial Officer (CFO) and Principal Accounting Officer, effective September 30, 2025. Mr. Gupta previously served as the Company's Vice President, Finance & Controller since June 2024.
- Bylaw Amendments: The Board amended and restated the Company's bylaws to update advance notice procedures for business proposals and director nominations.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. The document strictly reports on the appointment of a senior officer and the amendment of corporate bylaws.
Investor Verification Checklist
- Verify the background and prior experience of the newly appointed CFO, Ashoo Gupta, particularly his tenure at Kyverna Therapeutics and Myovant Sciences.
- Review the full text of the Amended and Restated Bylaws (Exhibit 3.1) to understand the specific changes to advance notice procedures for shareholders and director nominations.
- Confirm that no undisclosed family relationships or special transactions exist between Mr. Gupta and other company directors or officers, as stated in the filing.